Ionis Pharmaceuticals
IONS
322 hedge funds and large institutions have $6.11B invested in Ionis Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 84 increasing their positions, 114 reducing their positions, and 32 closing their positions.
53% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 32
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
24% more capital invested
Capital invested by funds: $4.93B → $6.11B (+$1.18B)
5% more funds holding
Funds holding: 307 → 322 (+15)
7.96% less ownership
Funds ownership: 94.26% → 86.3% (-8%)
21% less call options, than puts
Call options by funds: $77.5M | Put options by funds: $98M
26% less repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 114
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$76.9M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$49.7M |
| 3 |
BlackRock
New York
|
+$19.2M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$18.8M |
| 5 |
Two Sigma Investments
New York
|
+$18.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
-$40.6M |
| 2 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$32.8M |
| 3 |
ClearBridge Investments
New York
|
-$27.4M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$15.1M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
-$14.1M |
IONS Hedge Fund Activity: Q3 2018 in Review
322 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q3 2018, worth a combined $6.11B — up 24% from $4.93B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new IONS positions and 32 closed out — a net gain of 17 holders — while 84 added to existing stakes and 114 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $76.9M. The largest seller was OppenheimerFunds, cutting an estimated $40.6M.
- 322 institutional investors held Ionis Pharmaceuticals (IONS) as of Q3 2018, up from 307 in Q2 2018.
- Funds reported $6.11B of Ionis Pharmaceuticals stock for Q3 2018, up 24% quarter-over-quarter.
- 49 funds opened new Ionis Pharmaceuticals positions in Q3 2018 and 32 closed out, a net change of +17 holders.
- The largest Ionis Pharmaceuticals buyer in Q3 2018 was Fidelity Investments, an estimated $76.9M added.
- The largest Ionis Pharmaceuticals seller in Q3 2018 was OppenheimerFunds, an estimated $40.6M sold.
Based on aggregated 13F filings for Q3 2018.